Fig. 3

KMT2D is a key oncogene in pediatric ALL. a Mutational diagram of KMT2D. PHD, plant homeodomain; HMG, high mobility group domain; SET, Su (var)3–9 Enhancer of zeste and Trithorax domain; FYR, FY-rich domain. b Increased KMT2D mRNA expression in ALL samples. **, P < 0.01. c Higher expression levels of KMT2D in ALL data (retrieved from GSE13159). d Generation of Nalm-6 cells with stable knockdown of KMT2D. Three shRNA sequences displayed significant suppression of KMT2D expression. ***, P < 0.001. e, f, g Evaluation of the effect of KMT2D knockdown Nalm-6 cells on cell proliferation, cell apoptosis and cell cycle. *, P < 0.05; **, P < 0.01; ***, P < 0.001, N.S., no significance. h Volcano plot depicting differentially expressed genes between the KMT2D knockdown and control groups. i Bubble chart depicts Gene Ontology (GO) functional enrichment analysis of differentially expressed genes. g RT-qPCR analysis of selected genes identified as differentially expressed in RNA sequencing. GAPDH was used as an endogenous control to normalize for RNA quality. *, P < 0.05; **, P < 0.01; ***, P < 0.001, N.S., no significance